Matthew Frigault
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthew Frigault as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06550141 · Emapalumab Prevention of CAR-T Cell Associated ToxicitiesMarcela V. Maus, M.D.,Ph.D. · recruiting · Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT06026319 · CD79b-19 CAR T Cells in Non-Hodgkin LymphomaMarcela V. Maus, M.D.,Ph.D. · recruiting · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:38 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.N Engl J Med · 20201,046 citationsRCR 48.9
- Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.N Engl J Med · 2024418 citationsRCR 49.7
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.Ann Oncol · 2020377 citationsRCR 13.8
- 324 citationsRCR 11.8
- Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.Blood Adv · 2019162 citationsRCR 5.9
- Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.JAMA Oncol · 2020159 citationsRCR 7.0
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.J Clin Oncol · 2017158 citationsRCR 4.8
- 158 citationsRCR 6.9
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.Lancet Haematol · 2020144 citationsRCR 6.3
- Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.Blood · 2022139 citationsRCR 9.3